Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.

NCT ID: NCT03465579

Last Updated: 2025-01-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 261 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-23
• Study Completion Date: 2024-09-03

Brief Summary

BIOPSTAGE is a prospective, non-randomized, diagnostic, multi-cohort investigational study to evaluate the impact of pelvic Multi-parametric 3-Tesla magnetic resonance imaging (mp-3TMRI) and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and pre-surgical staging.

Detailed Description

The aim of this study is to characterize the diagnostic accuracy of both multi-parametric pelvic Magnetic Resonance Imaging (MRI) (T2-weighted, Diffusion Weighted Imaging (DWI), Dynamic Contrast Enhancement (DCE) and 68Ga-chelated Prostate Specific Membrane Antigen ligand (68Ga-PSMA) Positron Emission Tomography/Computed Tomography (PET /CT) in three cohorts of patients:

• COHORT 1 Guiding prostate biopsies in men with clinical suspicion and/or unconfirmed clinically-significant prostate cancer (CS-PCa) on initial prostate biopsy;
• COHORT 2 Targeting repeat prostate biopsy in patients on Active Surveillance (PRIAS Study), scheduled for PRIAS repeat biopsy;
• COHORT 3

Providing pelvic / whole-body pre-surgical staging in:

• 3a: men with high-risk PCa (HR-PCa);
• 3b: men candidates for nerve sparing surgery (NSS);

Conditions

68Ga-PSMA PET/CT Guided Prostate Biopsy; Mp-3TMRI Guided Prostate Biopsy; Prostate Cancer; TNM Staging; Diagnosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Cohort 1

Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy

Group Type: OTHER

pelvic MRI

Intervention Type: DIAGNOSTIC_TEST

multi-parametric pelvic MRI

68Ga-PSMA PET/CT

Intervention Type: DIAGNOSTIC_TEST

68Ga-PSMA PET/CT

Cohort 2

Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.

Group Type: OTHER

pelvic MRI

Intervention Type: DIAGNOSTIC_TEST

multi-parametric pelvic MRI

68Ga-PSMA PET/CT

Intervention Type: DIAGNOSTIC_TEST

68Ga-PSMA PET/CT

Cohort 3a

Men with high-risk PCa (HR-PCa) prior to radical surgery.

Group Type: OTHER

pelvic MRI

Intervention Type: DIAGNOSTIC_TEST

multi-parametric pelvic MRI

68Ga-PSMA PET/CT

Intervention Type: DIAGNOSTIC_TEST

68Ga-PSMA PET/CT

Cohort 3b

Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).

Group Type: OTHER

pelvic MRI

Intervention Type: DIAGNOSTIC_TEST

multi-parametric pelvic MRI

68Ga-PSMA PET/CT

Intervention Type: DIAGNOSTIC_TEST

68Ga-PSMA PET/CT

Interventions

pelvic MRI

multi-parametric pelvic MRI

Intervention Type: DIAGNOSTIC_TEST

68Ga-PSMA PET/CT

68Ga-PSMA PET/CT

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

Cohort 1 - Biopsy guidance in clinically-suspected PCa

1. Men aged 45 to 75 years old with clinically-suspected PCa candidated for either initial or repeat TRUS-guided prostate biopsy, meeting any of the following criteria:

a) Abnormal PSA metrics, defined as follows:

A rising and/or persistently elevated serum PSA (i.e PSA > 2.5ng/ml for men in the age group comprising 60 to 75 years old; PSA > 3.0ng/ml for men in the age group comprising 45 to 60 years old) and at least one of the following PSA-based metrics:

i. Percent free PSA (%fPSA) < 25% with PSA range 4-10ng/ml (NCCN); ii. PSA velocity (PSAvel) >0.35 ng/mL/y; iii. PSA density (PSAden) > 0.25ng/mL/cc iv. PSA > 10ng/ml, 50% risk of PCa (EAU) b) Suspicious digital rectal examination (DRE), 5-30% risk of PCa; c) Prostate Cancer Gene 3 (PCA3) > 35; d) Suspicious findings on first-round biopsy: i. A few Atypical Glands immediately adjacent to HG-PIN, 50% risk of PCa; ii. Atypical Small Acinar Proliferation, 40% of PCa; iii. Multifocal High-Grade Prostatic intraepithelial neoplasia (HG-PIN), 30% ; iv. Intraductal carcinoma as solitary finding, 90% of PCa;

Cohort 2 - Biopsy guidance on Active Surveillance

1. Histologically-proven adenocarcinoma of the prostate;

2. Age ≥ 18

3. Men should be fit for curative treatment;

4. Clinical stage T1c or T2;

5. Gleason score 3+3=6;

6. One or two biopsy cores invaded with prostate cancer:

1. If an MRI, including targeted biopsies on positive lesions, is done at inclusion, there is no limit in the number of positive cores (that is, more than two, and no limit in the % of cancer present in the cores);

7. PSA density (PSA D) less than 0.2;

8. PSA-level at diagnosis ≤ 10 ng/mL;

Cohort 3a - Pre-surgical TNM staging in high-risk prostate cancer

1. Male, aged 18 years or older;

2. Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);

3. Any of the PCa high risk features for Organ-Confined Disease (OCD):

• Clinical T stage ≥ T2c;
• Gleason Score ≥ 8;
• Serum PSA > 20 ng/mL;

4. Any of the PCa high-risk features for Locally-Advanced Disease (LAD):

• Clinical T stage ≥ T3b-T4 OR any T and clinical N1 disease;
• Gleason Score ≥ 8;
• Serum PSA > 20 ng/mL;

5. Routine clinical staging (CTscan ± Bone scan) performed within 12 weeks enrolment returning negative or equivocal results for distant metastatic disease;

Cohort 3b - pelvic TNM staging of prostate cancer prior to nerve-sparing radical prostatectomy

1. Male, aged 18 years or older;

2. Cyto / histological confirmation of PCa (i.e. TRUS-guided biopsies; TURP);

3. All of the following PCa-related features must be met for nerve-sparing (either mono- or bi-lateral):

• Clinical T stage ≤ T2b;
• Gleason Score ≤ 7 (3+4) and maximum one biopsy with Gleason > 6 at the ipsilateral side;
• Serum PSA < 10 ng/mL;

Exclusion Criteria

The participant may not enter the study if ANY of the following apply:

1. Hormone androgen deprivation therapy of any type within 6 months prior to enrollment.

2. Prior pelvic radiotherapy;

3. Sickle cell disease;

4. Insufficient renal function (eGFR < 30 mL/min/1.73 m2);

5. Hip prosthesis, vascular grafting or other conditions affecting imaging;

6. Contraindication to MRI, including but not restricted to: pacemaker or other electronic im-plants, known metal in the orbit, MR incompatible surgical or cerebral aneurysm clips, shrapnel, tattoos, non-removable body piercings (relative contraindications);

7. History of allergic reactions attributed to compounds of similar chemical or biologic com-position to 68Ga-PSMA or Gadolinium-based contrast agents used in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Federica Matteucci

Role: STUDY_CHAIR

IRST IRCCS

Locations

AUSL della Romagna

Forlì, FC, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)

Meldola, FC, Italy

Countries

Italy

Other Identifiers

IRST185.05

Identifier Type: -

Identifier Source: org_study_id